San Jose, United States
Cipherome, Inc. is at the forefront of merging AI-driven data analysis with healthcare, specifically targeting the prediction of adverse drug reactions (ADRs). Established in 2016, this United States headquartered company leverages its expertise in pharmacogenomics and bioinformatics to offer a unique software solution called Xentinel ™.
With a focus on Biopharma, Biotechnology, and Health Care, Cipherome positions itself as a pioneer in creating personalized drug safety and biomarker discovery platforms. Their mission is clear: to alleviate the economic, emotional, and societal burdens associated with ADRs.
The latest financial backing was a KRW19.50B Series B investment on 01 February 2022, attracted from top-tier investors like InterVest, Medivate Partners, Signite Partners, and Nautilus. This underlines the confidence of key players in Cipherome’s innovative approach to enhancing healthcare research through predictive analytics.
